NYSEAMERICAN:ATNMActinium Pharmaceuticals Stock Price, Forecast & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Actinium Pharmaceuticals.

Actinium Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Actinium Pharmaceuticals.

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) released its earnings results on Monday, June, 29th. The biotechnology company reported ($0.03) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.01. View Actinium Pharmaceuticals' earnings history.

3 brokers have issued 1 year price objectives for Actinium Pharmaceuticals' stock. Their forecasts range from $1.50 to $3.00. On average, they anticipate Actinium Pharmaceuticals' stock price to reach $2.25 in the next year. This suggests a possible upside of 616.6% from the stock's current price. View analysts' price targets for Actinium Pharmaceuticals.

Press coverage about ATNM stock has trended negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Actinium Pharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Actinium Pharmaceuticals.

Some companies that are related to Actinium Pharmaceuticals include Lineage Cell Therapeutics (LCTX), Immunoprecise Antibodies (IPA), Predictive Technology Group (PRED), Arix Bioscience (ARIX), Senesco Technologies (ELOX), CorMedix (CRMD), 22nd Century Group (XXII), Ampliphi Biosciences (APHB), Ampio Pharmaceuticals (AMPE), Helix Biopharma (HBP), Oncolytics Biotech (ONC), AquaBounty Technologies (AQB), Ibio (IBIO), Navidea Biopharmaceuticals (NAVB) and Orgenesis (ORGS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Opko Health (OPK), TransEnterix (TRXC), Tandem Diabetes Care (TNDM), Cancer Genetics (CGIX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Align Technology (ALGN).

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ATNM stock can currently be purchased for approximately $0.31.

Actinium Pharmaceuticals has a market capitalization of $124.08 million. Actinium Pharmaceuticals employs 30 workers across the globe.

The official website for Actinium Pharmaceuticals is www.actiniumpharmaceuticals.com.

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875.